CORRESP Filing
bioAffinity Technologies, Inc.
Date: May 2, 2025 · CIK: 0001712762 · Accession: 0001641172-25-008449
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286921
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed May 2, 2025 File No: 333-286921
Dear Ms. Sawicki:
bioAffinity Technologies, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-286921), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Monday, May 5, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm May 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed May 2, 2025 File No: 333-286921 Dear Ms. Sawicki: bioAffinity Technologies, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-286921), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Monday, May 5, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request for acceleration has been granted. Very truly yours, BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: Chief Executive Officer cc: Leslie Marlow, Blank Rome LLP